Cefonicid

Catalog No.
S585679
CAS No.
61270-58-4
M.F
C18H18N6O8S3
M. Wt
542.6 g/mol
Availability
* This item is exclusively intended for research purposes and is not designed for human therapeutic applications or veterinary use.
Cefonicid

CAS Number

61270-58-4

Product Name

Cefonicid

IUPAC Name

(6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Molecular Formula

C18H18N6O8S3

Molecular Weight

542.6 g/mol

InChI

InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1

InChI Key

DYAIAHUQIPBDIP-AXAPSJFSSA-N

SMILES

C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O

Solubility

8.95e-01 g/L

Synonyms

Cefonicid, Cefonicid Disodium Salt, Cefonicid Monosodium, Cefonicid Monosodium Salt, Cefonicid, Sodium, Monocid, SK and F 75073, SK and F-75073, SK and F75073, SKF 75073 2, SKF-75073-2, SKF750732, Sodium Cefonicid

Canonical SMILES

C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O

Isomeric SMILES

C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O

Antimicrobial Activity:

  • Researchers have investigated the in vitro and in vivo activity of cefonicid against a range of bacterial strains. These studies have helped to determine its effectiveness against various infections. Source: National Institutes of Health, [National Center for Biotechnology Information: ]

Pharmacokinetic and Pharmacodynamic Properties:

  • Studies have been conducted to understand how cefonicid is absorbed, distributed, metabolized, and excreted in the body. This information is essential for determining appropriate dosing regimens and potential drug interactions. Source: National Institutes of Health, [National Center for Biotechnology Information: ]

Comparison with other antibiotics:

  • Cefonicid has been compared to other antibiotics in terms of efficacy and safety in the treatment of specific infections. These studies help healthcare professionals make informed decisions about the best course of treatment for their patients. Source: National Institutes of Health, [National Center for Biotechnology Information: ]

Exploring new formulations and delivery methods:

  • Researchers are investigating new ways to formulate and deliver cefonicid to improve its effectiveness and patient tolerability. This includes exploring new dosage forms and delivery routes, such as sustained-release formulations or inhalable forms. Source: National Institutes of Health, [National Center for Biotechnology Information: ]

Physical Description

Solid

XLogP3

-1.9

UNII

6532B86WFG

Related CAS

61270-78-8 (di-hydrochloride salt)

GHS Hazard Statements

Aggregated GHS information provided by 2 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.;
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin];
H334 (100%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory];
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Pictograms

Health Hazard Irritant

Irritant;Health Hazard

Other CAS

61270-58-4
61270-78-8

Wikipedia

Cefonicid

Biological Half Life

4.5 hours

Dates

Modify: 2023-08-15

Explore Compound Types